Meningococcemia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Meningococcemia}} | {{Meningococcemia}} | ||
{{CMG}} ; {{AE}} {{Ammu}} | |||
==Overview== | |||
==Cost-effective Analysis== | |||
*As part of the evaluation of the adolescent vaccination program, a cost-effectiveness analysis was performed to compare the cost-effectiveness of the following three vaccination strategies: <ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm}}</ref> | |||
:* A single dose at age 11 years | |||
:* A single dose at age 15 years | |||
:* A dose at age 11 years with a booster dose at age 16 years. The economic costs and benefits of these meningococcal vaccination strategies in adolescents were assessed from a societal perspective <ref name="pmid11934772">{{cite journal| author=Trotter CL, Edmunds WJ| title=Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. | journal=BMJ | year= 2002 | volume= 324 | issue= 7341 | pages= 809 | pmid=11934772 | doi= | pmc=PMC100788 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11934772 }} </ref><ref name="pmid15867028">{{cite journal| author=Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team| title=Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. | journal=Pediatrics | year= 2005 | volume= 115 | issue= 5 | pages= 1220-32 | pmid=15867028 | doi=10.1542/peds.2004-2514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15867028 }} </ref>. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
Revision as of 20:52, 19 November 2014
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Meningococcemia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Meningococcemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Cost-effective Analysis
- As part of the evaluation of the adolescent vaccination program, a cost-effectiveness analysis was performed to compare the cost-effectiveness of the following three vaccination strategies: [1]
References
- ↑ "The Centers for Disease Control and Prevention(CDC)".
- ↑ Trotter CL, Edmunds WJ (2002). "Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales". BMJ. 324 (7341): 809. PMC 100788. PMID 11934772.
- ↑ Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team (2005). "Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States". Pediatrics. 115 (5): 1220–32. doi:10.1542/peds.2004-2514. PMID 15867028.